MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review To judge various intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Principal trial goals ended up To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis clients, while among the exploratory goals https://jamesw110jhm0.boyblogguide.com/profile